North America:
North America Interleukin-10 (IL-10) pipeline market, supported by its advanced healthcare infrastructure and increased investments in research and development. The United States is the primary driver of this market due to the prevalence of autoimmune and inflammatory diseases, which IL-10 therapies aim to treat. In addition, the regulatory framework in the U.S. encourages the...